PROTACs Roundtable: Bertozzi and Deshaies

1

Introduction

00:00 • 2min

2

The Difference Between Protects and Molecular Gluses

01:54 • 2min

3

Glusan Refamid Salgines - Is That Right?

04:13 • 2min

4

I Thinks Doubt Thes Continued Interest Frompharmacuticals, Mmonty, Nationals in the Area.

06:13 • 2min

5

Protas and Moleculegles

07:49 • 2min

6

Is Induced Proximity a Drug Development Approach?

10:02 • 2min

7

How to Design a New Protac?

11:44 • 3min

8

Extra Cellular Proteins - Why Are They Undruggable?

14:42 • 4min

9

The Li Taxi Approach to Protein Recycling

19:06 • 2min

10

Oncology Drugs - Is There a Resistance Development Mechanism?

21:36 • 2min

11

Mutation of the Ubiquitin Ligase

23:27 • 2min

12

Cancer Without Lisesomes Ano Mamalion Sel

25:04 • 2min

13

Is Protax an Induced Proximity?

26:47 • 3min

14

The Concept of Proximity Induced Degradation Extends Well Beyond Proteins

29:19 • 2min

15

Is There Any Indication of the Efficacy of Protexs in the Clinic?

31:44 • 2min

16

Is There a Way to Deliver Drugs?

33:33 • 7min